Out-licensing

Scientists at the forefront of regenerative medicine based at the Biomatcell Vinn Excellence Center of Biomaterials have identified this small molecule platform with these unique osteogenic differentiating properties and are now looking to develop them.

Here at Innovaro Pharmalicensing we are looking to identify partner companies that can develop a unique group of small molecules capable of enhancing osteogenic differentiation of stem cells.

The Biomatcell Center in Sweden who have identified and protected this small molecule platform was set up in 2007 as a Swedish National Center for Research and Development of next generation biomaterial- based medical devices and clinical treatments.

The State-of-the-Art Center has tested the molecules and have subsequent in vitro data that demonstrates their ability to enhance osteogenic differentiation of human mesenchymal stem cells (hMSCs), which makes them potential candidates to treat bone defects, trauma and bone related diseases. The differentiated stem cells could also be useful to enhance ossointegration of orthopaedic implants into the body as well as dental implants.

 

Early Stage

The client is looking for partners to develop these molecules further. A joint collaboration could be a good option. Companies of interest should include those presently developing stem cell therapies for musculoskeletal indications or orthopaedic implant integration.